ddAC-mini CTC — Competitive Intelligence Brief

ddAC-mini CTC (ddAC-mini CTC) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted therapy. Area: Oncology.

phase 3 Targeted therapy Multiple molecular targets Oncology Small molecule

Target snapshot

ddAC-mini CTC (ddAC-mini CTC) — The Netherlands Cancer Institute. ddAC-mini CTC is a targeted therapy that uses a combination of drugs to target cancer cells.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ddAC-mini CTC TARGET	ddAC-mini CTC	The Netherlands Cancer Institute	phase 3	Targeted therapy	Multiple molecular targets
Combination 1	combination-1	Pfizer	marketed	Combination therapy	Multiple molecular targets
TQB2440 injection + Trastuzumab + Docetaxel	TQB2440 injection + Trastuzumab + Docetaxel	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Targeted therapy, monoclonal antibody, chemotherapy	PD-1, HER2/neu
NALIRIFOX plus targeted therapy	NALIRIFOX plus targeted therapy	Shanghai Zhongshan Hospital	phase 3	Combination chemotherapy with targeted therapy	Topoisomerase I, thymidylate synthase, and variable molecular targets depending on targeted therapy partner
FOLFOX plus targeted therapy	FOLFOX plus targeted therapy	Shanghai Zhongshan Hospital	phase 3	Combination chemotherapy plus targeted therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted therapy class)

1. The Netherlands Cancer Institute · 1 drug in this class